Goldman Sachs’s ANACOR PHARMACEUTICALS INC COM ANAC Stock Holding History

Goldman Sachs’s Portfolio ANAC Stock Details ANAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-785,000	Closed	-$42M	–	7596
2016 Q1	$42M	Buy	785,000 +462,500	+143%	+$34.1M	0.01%	1201
2015 Q4	$36.4M	Buy	322,500 +164,100	+104%	+$18.1M	0.01%	1348
2015 Q3	$18.6M	Sell	158,400 -19,400	-11%	-$2.53M	0.01%	1768
2015 Q2	$13.8M	Buy	177,800 +139,300	+362%	+$9.13M	﹤0.01%	2087
2015 Q1	$2.23M	Buy	+38,500	New	+$1.63M	﹤0.01%	3678

Other funds holding ANAC

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

CIM

CIM Investment Management Pittsburgh, Pennsylvania $375M AUM 32.03% 1-Year Est. Return

Goldman Sachs's ANAC Position: Q2 2016 in Review

Goldman Sachs sold out of ANACOR PHARMACEUTICALS INC COM (ANAC) in Q2 2016, closing a stake of 1,561,729 shares — an estimated $83.5M sold.

Goldman Sachs first reported a position in ANAC in Q2 2013 and held it in 10 quarters. The position peaked at $83.5M in Q1 2016. 2 funds tracked by Wall St. Rank hold ANAC as of Q2 2016.

Goldman Sachs reported no remaining ANACOR PHARMACEUTICALS INC COM position as of Q2 2016 after selling out during the quarter.
Goldman Sachs sold 1,561,729 ANACOR PHARMACEUTICALS INC COM shares in Q2 2016, an estimated $83.5M.
Goldman Sachs first reported a position in ANACOR PHARMACEUTICALS INC COM in Q2 2013 and held it in 10 quarters.
Goldman Sachs's ANACOR PHARMACEUTICALS INC COM position peaked at $83.5M in Q1 2016.
2 funds tracked by Wall St. Rank held ANACOR PHARMACEUTICALS INC COM as of Q2 2016.

Based on Goldman Sachs's 13F filing for Q2 2016, filed 15 Aug 2016.